Patents by Inventor Fumihiko Akahoshi
Fumihiko Akahoshi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10717731Abstract: A compound represented by general formula [I] wherein X represents N or the like, Y represents CH or the like; RA represents a cycloalkyl group which may be substituted or the like, R1 represents an alkyl group or the like, R2 represents an alkyl group which may be substituted or the like, R3 represents a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof has an inhibitory activity on aldosterone synthetase, and is useful as a prophylactic and/or therapeutic agent for various diseases or symptoms associated with aldosterone.Type: GrantFiled: October 21, 2016Date of Patent: July 21, 2020Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Ryo Sakakibara, Hideki Ushirogochi, Wataru Sasaki, Yuichi Onda, Minami Yamaguchi, Fumihiko Akahoshi
-
Patent number: 10329263Abstract: This invention provides a novel disubstituted 1,2,4-triazine compound or a pharmaceutically acceptable salt thereof, which has an aldosterone synthetase inhibitory activity and is useful for preventing and/or treating various diseases or conditions associated with aldosterone; a method for preparing it; use of it; as well as a pharmaceutical composition comprising it as an active ingredient. A compound of the general formula [I]: wherein RA is, for example, a group of the following formula (A-1): wherein ring A1 is, for example, a cycloalkyl group which may be substituted, and RB is, for example, a monocyclic cycloalkyl group, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 22, 2018Date of Patent: June 25, 2019Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Hideki Ushirogochi, Wataru Sasaki, Yuichi Onda, Ryo Sakakibara, Fumihiko Akahoshi
-
Publication number: 20180312503Abstract: A compound represented by general formula [I] wherein X represents N or the like, Y represents CH or the like; RA represents a cycloalkyl group which may be substituted or the like, R1 represents an alkyl group or the like, R2 represents an alkyl group which may be substituted or the like, R3 represents a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof has an inhibitory activity on aldosterone synthetase, and is useful as a prophylactic and/or therapeutic agent for various diseases or symptoms associated with aldosterone.Type: ApplicationFiled: October 21, 2016Publication date: November 1, 2018Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Ryo SAKAKIBARA, Hideki USHIROGOCHI, Wataru SASAKI, Yuichi ONDA, Minami YAMAGUCHI, Fumihiko AKAHOSHI
-
Publication number: 20180305326Abstract: This invention provides a novel disubstituted 1,2,4-triazine compound or a pharmaceutically acceptable salt thereof, which has an aldosterone synthetase inhibitory activity and is useful for preventing and/or treating various diseases or conditions associated with aldosterone; a method for preparing it; use of it; as well as a pharmaceutical composition comprising it as an active ingredient. A compound of the general formula [I]: wherein RA is, for example, a group of the following formula (A-1): wherein ring A1 is, for example, a cycloalkyl group which may be substituted, and RB is, for example, a monocyclic cycloalkyl group, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: June 22, 2018Publication date: October 25, 2018Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Hideki USHIROGOCHI, Wataru SASAKI, Yuichi ONDA, Ryo SAKAKIBARA, Fumihiko AKAHOSHI
-
Patent number: 10029993Abstract: This invention provides a novel disubstituted 1,2,4-triazine compound or a pharmaceutically acceptable salt thereof, which has an aldosterone synthetase inhibitory activity and is useful for preventing and/or treating various diseases or conditions associated with aldosterone; a method for preparing it; use of it; as well as a pharmaceutical composition comprising it as an active ingredient. A compound of the general formula [I]: wherein RA is, for example, a group of the following formula (A-1): wherein ring A1 is, for example, a cycloalkyl group which may be substituted, and RB is, for example, a monocyclic cycloalkyl group, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: April 23, 2015Date of Patent: July 24, 2018Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Hideki Ushirogochi, Wataru Sasaki, Yuichi Onda, Ryo Sakakibara, Fumihiko Akahoshi
-
Publication number: 20170044115Abstract: This invention provides a novel disubstituted 1,2,4-triazine compound or a pharmaceutically acceptable salt thereof, which has an aldosterone synthetase inhibitory activity and is useful for preventing and/or treating various diseases or conditions associated with aldosterone; a method for preparing it; use of it; as well as a pharmaceutical composition comprising it as an active ingredient. A compound of the general formula [I]: wherein RA is, for example, a group of the following formula (A-1): wherein ring A1 is, for example, a cycloalkyl group which may be substituted, and RB is, for example, a monocyclic cycloalkyl group, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: April 23, 2015Publication date: February 16, 2017Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Hideki USHIROGOCHI, Wataru SASAKI, Yuichi ONDA, Ryo SAKAKIBARA, Fumihiko AKAHOSHI
-
Patent number: 8754032Abstract: A concomitant agent to be used simultaneously or separately, comprising a combination of (a) 3-{(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl}thiazolidine, a salt of the compound with an organic or inorganic and mono- or di-basic acid or a solvate thereof, and (b) at least one kind of active ingredient selected from the group consisting of an active ingredient of a pharmaceutical agent selected from (i) an antidiabetic drug, (ii) a lipid lowering drug, (iii) an antihypertensive drug, (iv) a therapeutic drug for diabetic complications, (v) an antiobesity drug, (vi) an antiplatelet drug and (vii) an anticoagulant, a pharmaceutically acceptable salt thereof and a solvate thereof.Type: GrantFiled: June 2, 2006Date of Patent: June 17, 2014Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Yuji Abe, Jun Anabuki, Fumihiko Akahoshi
-
Patent number: 8604198Abstract: The present invention provides 3-{(2S,4S)-4-[4-(3-methyl -1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2 -ylcarbonyl}thiazolidine (compound I) useful as a dipeptidyl peptidase-IV inhibitor, which has superior properties of stability and hygroscopicity, and reproducible crystal structure, and a production method thereof.Type: GrantFiled: July 29, 2011Date of Patent: December 10, 2013Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Tomohiro Yoshida, Hiroshi Sakashita, Naoko Ueda, Shinji Kirihara, Satoru Uemori, Reiko Tsutsumiuchi, Fumihiko Akahoshi
-
Publication number: 20110282058Abstract: The present invention provides 3-{(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl}thiazolidine (compound I) useful as a dipeptidyl peptidase-IV inhibitor, which has superior properties of stability and hygroscopicity, and reproducible crystal structure, and a production method thereof.Type: ApplicationFiled: July 29, 2011Publication date: November 17, 2011Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Tomohiro YOSHIDA, Hiroshi SAKASHITA, Naoko UEDA, Shinji KIRIHARA, Satoru UEMORI, Reiko TSUTSUMIUCHI, Fumihiko AKAHOSHI
-
Patent number: 8003790Abstract: The present invention provides 3-{(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl}thiazolidine (compound I) useful as a dipeptidyl peptidase-IV inhibitor, which has superior properties of stability and hygroscopicity, and reproducible crystal structure, and a production method thereof.Type: GrantFiled: February 17, 2006Date of Patent: August 23, 2011Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Tomohiro Yoshida, Hiroshi Sakashita, Naoko Ueda, Shinji Kirihara, Satoru Uemori, Reiko Tsutsumiuchi, Fumihiko Akahoshi
-
Publication number: 20100305139Abstract: The present invention provides a pharmaceutical agent for the treatment and/or prophylaxis of abnormal blood glucose and lipid metabolism associated with eating, for which a sufficient treatment method or a therapeutic drug has not been found.Type: ApplicationFiled: August 11, 2010Publication date: December 2, 2010Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Yuji ABE, Aki KUSUNOKI, Yoshiharu HAYASHI, Fumihiko AKAHOSHI
-
Patent number: 7790725Abstract: A thiazolidine derivative represented by the formula (I) wherein each symbol is as defined in the specification, and a pharmaceutically acceptable salt thereof exhibit a potent DPP-IV inhibitory activity, and can be provided as an agent for the prophylaxis or treatment of diabetes, an agent for the prophylaxis or treatment of obesity and the like.Type: GrantFiled: July 9, 2007Date of Patent: September 7, 2010Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Hiroshi Sakashita, Tomohiro Yoshida, Hiroshi Kitajima, Masahiro Takeuchi, Yoshihito Tanaka, Takuya Yoshimura, Fumihiko Akahoshi, Yoshiharu Hayashi
-
Publication number: 20090216016Abstract: The present invention provides 3-{(2S,4S)-4-[4-(3-methyl-1-phenyl-1H -pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl}thiazolidine (compound I) useful as a dipeptidyl peptidase-IV inhibitor, which has superior properties of stability and hygroscopicity, and reproducible crystal structure, and a production method thereof.Type: ApplicationFiled: February 17, 2006Publication date: August 27, 2009Applicant: MITSUBISHI PHARMA CORPORATIONInventors: Tomohiro Yoshida, Hiroshi Sakashita, Naoko Ueda, Shinji Kirihara, Satoru Uemori, Reiko Tsutsumiuchi, Fumihiko Akahoshi
-
Publication number: 20090088442Abstract: The present invention provides a pharmaceutical agent for the treatment and/or prophylaxis of abnormal blood glucose and lipid metabolism associated with eating, for which a sufficient treatment method or a therapeutic drug has not been found.Type: ApplicationFiled: April 26, 2006Publication date: April 2, 2009Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Yuji Abe, Aki Kusunoki, Yoshiharu Hayashi, Fumihiko Akahoshi
-
Publication number: 20090082256Abstract: A concomitant agent to be used simultaneously or separately, comprising a combination of (a) 3-{(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl}thiazolidine, a salt of the compound with an organic or inorganic and mono- or di-basic acid or a solvate thereof, and (b) at least one kind of active ingredient selected from the group consisting of an active ingredient of a pharmaceutical agent selected from (i) an antidiabetic drug, (ii) a lipid lowering drug, (iii) an antihypertensive drug, (iv) a therapeutic drug for diabetic complications, (v) an antiobesity drug, (vi) an antiplatelet drug and (vii) an anticoagulant, a pharmaceutically acceptable salt thereof and a solvate thereof.Type: ApplicationFiled: June 2, 2006Publication date: March 26, 2009Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Yuji Abe, Jun Anabuki, Fumihiko Akahoshi
-
Patent number: 7504423Abstract: Compounds represented by the ?-amino acid derivative or a pharmaceutically acceptable salt thereof of the present invention have a therapeutic effect due to a DPP-IV inhibitory action and useful as pharmaceutical agents for the treatment and/or prophylaxis of diseases relating to a DPP-IV inhibitor.Type: GrantFiled: December 10, 2004Date of Patent: March 17, 2009Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Fumihiko Akahoshi, Yoshiharu Hayashi
-
Publication number: 20070259880Abstract: A thiazolidine derivative represented by the formula (I) wherein each symbol is as defined in the specification, and a pharmaceutically acceptable salt thereof exhibit a potent DPP-IV inhibitory activity, and can be provided as an agent for the prophylaxis or treatment of diabetes, an agent for the prophylaxis or treatment of obesity and the like.Type: ApplicationFiled: July 9, 2007Publication date: November 8, 2007Applicant: MITSUBISHI PHARMA CORPORATIONInventors: Hiroshi SAKASHITA, Tomohiro YOSHIDA, Hiroshi KITAJIMA, Masahiro TAKEUCHI, Yoshihito TANAKA, Takuya YOSHIMURA, Fumihiko AKAHOSHI, Yoshiharu HAYASHI
-
Publication number: 20070049619Abstract: Compounds represented by the ?-amino acid derivative or a pharmaceutically acceptable salt thereof of the present invention have a therapeutic effect due to a DPP-IV inhibitory action and useful as pharmaceutical agents for the treatment and/or prophylaxis of diseases relating to a DPP-IV inhibitor.Type: ApplicationFiled: December 10, 2004Publication date: March 1, 2007Applicant: Mitsubishi Phama CorporationInventors: Fumihiko Akahoshi, Yoshiharu Hayashi
-
Publication number: 20060173056Abstract: The present invention aims at providing compounds having therapeutic effects due to a DPP-IV inhibitory action, and satisfactory as pharmaceutical products. The present inventors have found that derivatives having a substituent introduced into the ?-position of proline represented by the formula (I) wherein each symbol is as defined in the specification, have a potent DPP-IV inhibitory activity, and completed the present invention by increasing the stability.Type: ApplicationFiled: February 10, 2006Publication date: August 3, 2006Inventors: Hiroshi Kitajima, Hiroshi Sakashita, Fumihiko Akahoshi, Yoshiharu Hayashi
-
Patent number: 7074794Abstract: The present invention aims at providing compounds having therapeutic effects due to a DPP-IV inhibitory action, and satisfactory as pharmaceutical products. The present inventors have found that derivatives having a substituent introduced into the ?-position of proline represented by the formula (I) wherein each symbol is as defined in the specification, have a potent DPP-IV inhibitory activity, and completed the present invention by increasing the stability.Type: GrantFiled: August 10, 2001Date of Patent: July 11, 2006Assignee: Mitsubishi Pharma CorporationInventors: Hiroshi Kitajima, Hiroshi Sakashita, Fumihiko Akahoshi, Yoshiharu Hayashi